arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

MANNKIND CORP

MNKD
$3.35 ▼ -0.13 (-3.87%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Bullish
auto_awesome

Analytical Summary

MANNKIND CORP shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.0B
Dividend Yield —
Revenue Growth 22.2% ↘
Op. Margin 11.1% ↘
ROIC 53.3% ↗
FCF / Share $0.04 ↘
Trailing P/E 167.5x
Price / Book —
FCF Yield 1.3%
Debt / Equity -6.95
info Valuation on last close. End-of-day price, Sep 23, 2026.

35-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$348.97M
↑ +22.2% —
Net Income Profit after all expenses
$5.86M
↓ -78.7% —
Operating Margin Operating profit as % of sales
11.1%
↓ -56.3% 59th
FCF / Share Free cash flow per share
$0.04
↓ -62.5% —
Long-Term Debt Long-term obligations
$354.64M
↑ +883.7% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
45
Returns
33
Financial Health ↓
82
Cash Quality ↑
89

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 35 years · 85 quarters